STING1 and breast carcinoma: Zierhut et al. showed that STING is an essential determining factor of mitotic cell death in Taxol-treated breast cancer cells in vitro.113 Similarly, recent studies have revealed that PARP inhibitors can affect cGAS–STING signaling and antitumor immunity, as indicated by assessments of the tumor response in mouse models of transplantable ovarian and colorectal cancers.101,102 Regardless of the associated challenges, it is obvious that identification of agents that rapidly and precisely target centrosomes will be clinically beneficial for certain patients.